TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7607766

Group type: EXPERIMENTAL
Intervention: celiprolol 200‐400 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: metoprolol 100‐200 mg/day
Number of subjects: 40
Study: 2094056

Group type: EXPERIMENTAL
Intervention: Combined hormone substitution and Cavinton adjuvant therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hormone substitution therapy
Number of subjects: 40
Study: 332369

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 150
Study: 31994954

Group type: EXPERIMENTAL
Intervention: Comprehensive care plus asthma intervention program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comprehensive care alone
Number of subjects: 63
Study: 31179002

Group type: EXPERIMENTAL
Intervention: NIV-supported ACT
Number of subjects: 14

Group type: COMPARATOR
Intervention: ACT alone
Number of subjects: 14
Study: 29174618

Group type: EXPERIMENTAL
Intervention: Fibered Platinum Coils (FPCs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vascular Plugs (VPs)
Number of subjects: 100
Study: 25165064

Group type: EXPERIMENTAL
Intervention: RECT[active] + rTMS[active] (Group-A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: RECT[sham] + rTMS[active] (Group-B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: RECT[active] + rTMS[sham] (Group-C)
Number of subjects: 36
Study: 24337077

Group type: EXPERIMENTAL
Intervention: 15C (payment contingent on smoking abstinence across all 15 study days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2C (payment contingent on smoking abstinence for just the final 2 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15C
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2C
Number of subjects: 0
Study: 23061804

Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 0
Study: 20061926

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 47

Group type: COMPARATOR
Intervention: other hypotensives
Number of subjects: 47
Study: 17525087

Group type: EXPERIMENTAL
Intervention: Epirubicin, leucovorin, 5‐fluorouracil and etoposide (ELFE regimen)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Epirubicin, leucovorin, 5‐fluorouracil and etoposide (ELFE regimen) in node-positive patients
Number of subjects: 228

Group type: COMPARATOR
Intervention: Surgery alone in node-positive patients
Number of subjects: 228
Study: 15766366

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) b.i.d. for 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo b.i.d. for 3 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14670773

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) treatment, 1 IU/kg/week, administered via daily subcutaneous injections for 12 months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 20
Study: 10620211

Group type: EXPERIMENTAL
Intervention: Thyroxine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 8880055

Group type: EXPERIMENTAL
Intervention: Citalopram (10, 20, 40, 80 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluoxetine (3-week intervals)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25, 50, 100, 200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paroxetine (10, 20, 40, 80 mg)
Number of subjects: 24
Study: 1804757

Group type: EXPERIMENTAL
Intervention: Omeprazole alone for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole plus roxithromycin for 2 weeks
Number of subjects: 0
Study: 6347173

Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (antacid and placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Climbers with severe AMS symptoms
Number of subjects: 45
Study: 28531324

Group type: EXPERIMENTAL
Intervention: Vignette depicting a grandparent in need
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Vignette depicting a grandchild in need
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Vignette granddaughter
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Respondents who are single, in worse functional health, and whose children all migrated
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Respondents who coresided with children
Number of subjects: 989
Study: 30459575

Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulation (EIMS) at 2 Hz for ten sessions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulation (EIMS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 24
Study: 26086325

Group type: EXPERIMENTAL
Intervention: Stretching device
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 24556829

Group type: EXPERIMENTAL
Intervention: low‐energy diet (800‐1,000 kcal/day for 8 weeks followed by 1,200 kcal/day for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: normal healthy foods (for 16 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: low‐energy diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: normal healthy foods
Number of subjects: 60
Study: 21931125

Group type: EXPERIMENTAL
Intervention: Nocturnal every-other-day OL-HDF (same convective volume for 6 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nocturnal every-other-day OL-HDF (higher convective volume for 6 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nocturnal every-other-day OL-HDF
Number of subjects: 26
Study: 19969021

Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 17947823

Group type: EXPERIMENTAL
Intervention: Meridian HP60M IOL
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Acrysof MA60BM IOL
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Acrysof MA30BA IOL
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: AMO Clariflex IOL
Number of subjects: 600

Group type: COMPARATOR
Intervention: All IOLs
Number of subjects: 600
Study: 16238217

Group type: EXPERIMENTAL
Intervention: Conventional cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both conventional and ART methods
Number of subjects: 15

Group type: COMPARATOR
Intervention: Failures in restorations
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional and ART methods
Number of subjects: 15
Study: 12404887

Group type: EXPERIMENTAL
Intervention: 10 mg dequalinium chloride, treated once per day for 6 days
Number of subjects: 180

Group type: COMPARATOR
Intervention: 200 mg povidone iodine, treated once per day for 6 days
Number of subjects: 180
Study: 9593495

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR) and therapy (PT and OT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG) receiving physiotherapy (PT) and occupational therapy (OT)
Number of subjects: 24
Study: 7836712

Group type: EXPERIMENTAL
Intervention: Alcohol withdrawal for 1 week
Number of subjects: 16
Study: 2963509

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone premedication
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 31243480

Group type: EXPERIMENTAL
Intervention: RGB-10
Number of subjects: 250

Group type: COMPARATOR
Intervention: Reference teriparatide
Number of subjects: 250
Study: 30721201

Group type: EXPERIMENTAL
Intervention: Retinalamine (#10, intramuscularly, one course)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Traditional neuroprotective therapy
Number of subjects: 146
Study: 26747497

Group type: EXPERIMENTAL
Intervention: Patients with carotid artery disease
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 60
Study: 24622716

Group type: EXPERIMENTAL
Intervention: SYR-472 12.5 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: SYR-472 25 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: SYR-472 50 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: SYR-472 100 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: SYR-472 200 mg
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 23011525

Group type: EXPERIMENTAL
Intervention: Monotherapy (valsartan or amlodipine)
Number of subjects: 10545

Group type: COMPARATOR
Intervention: Combination therapy (including hydrochlorothiazide)
Number of subjects: 10545

Group type: COMPARATOR
Intervention: Combination therapy controlled vs uncontrolled
Number of subjects: 10545
Study: 19930237

Group type: EXPERIMENTAL
Intervention: Children's Friendship Training (CFT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 100
Study: 17350216

Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost (60-microg dose administered intravenously starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo (administered starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost and Placebo
Number of subjects: 322
Study: 16333148

Group type: EXPERIMENTAL
Intervention: Balance training with visual feedback, three sessions per week for six weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Balance training with visual feedback
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 12490752

Group type: EXPERIMENTAL
Intervention: Study care protocol (no-rinse skin cleanser after each episode and application of a barrier cream with durable properties after the first incontinence episode of each shift)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care regimen (soap and water cleansing after each incontinence episode, followed by application of a moisturizing lotion)
Number of subjects: 32
Study: 9824790

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Doxazosin plus finasteride
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Terazosin plus finasteride
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo plus finasteride
Number of subjects: 90
Study: 8013758

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg per os, at -5 and -1 h before the clamp)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2786673

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g six times per day via gastric tube)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ranitidine (six 50‐mg to six 100‐mg doses per day intravenously)
Number of subjects: 32
Study: 5354877

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt) at 55 mug
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isoprenaline sulphate inhalation at 550 mug
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE(1)) inhalation (free acid or neutral triethanolamine salt)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt)
Number of subjects: 6
Study: 15215066

Group type: EXPERIMENTAL
Intervention: Post-KR interval of 3 seconds
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Post-KR interval of 6 seconds
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Post-KR interval of 12 seconds
Number of subjects: 90
Study: 31791008

Group type: EXPERIMENTAL
Intervention: Ending the abusive relationship
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Safety planning strategies
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Baseline experiences of IPV
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Final interviews after ending the relationship
Number of subjects: 11
Study: 31448013

Group type: EXPERIMENTAL
Intervention: Standard airtime incentive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double airtime incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily follow-up reminder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incentivised mHealth solution
Number of subjects: 0
Study: 28735755

Group type: EXPERIMENTAL
Intervention: 30min of vigorous‐intensity exercise 24h prior to the first doxorubicin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: No vigorous exercise for 72h prior to treatment (control)
Number of subjects: 24
Study: 25896256

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine challenge during a 55-minute resting-state scan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study: 24379055

Group type: EXPERIMENTAL
Intervention: Fixed oral combination of hyaluronic acid and chondroitin-sulphate (HA+CS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21457209

Group type: EXPERIMENTAL
Intervention: Adapalene-benzoyl peroxide gel
Number of subjects: 243

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 243
Study: 19598021

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 191

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 191
Study: 17639559

Group type: EXPERIMENTAL
Intervention: Slim339 (Garcinia cambogia extract with calcium pantothenate and herbal extracts)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15851216

Group type: EXPERIMENTAL
Intervention: Enhanced detection in dual-chamber ICD
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (rate-only detection)
Number of subjects: 149
Study: 11468265

Group type: EXPERIMENTAL
Intervention: Routine testing before cataract surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal occult bleed testing
Number of subjects: 0
Study: 9770086

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 8093148

Group type: EXPERIMENTAL
Intervention: Enhanced education programme (four personalised booklets, sent by post)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Control group (conventional oral education at outpatient or surgery visits)
Number of subjects: 801
Study: 3065411

Group type: EXPERIMENTAL
Intervention: Low-sodium intervention directed at women through mass media techniques
Number of subjects: 2211

Group type: COMPARATOR
Intervention: Control town (observed without intervention)
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Low-sodium intervention directed at men
Number of subjects: 2211
Study: 31189406

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 0
Study: 28826348

Group type: EXPERIMENTAL
Intervention: Tablet computer-based intervention
Number of subjects: 32
Study: 26049672

Group type: EXPERIMENTAL
Intervention: Intervention (coaches attended 2 coach education sessions)
Number of subjects: 76
Study: 23864141

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CM) added to methotrexate (MTX) and methylprednisolone (MP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Methotrexate (MTX) and methylprednisolone (MP) alone
Number of subjects: 32
Study: 21600570

Group type: EXPERIMENTAL
Intervention: Psychological intervention to reduce stress
Number of subjects: 16

Group type: COMPARATOR
Intervention: High stress group (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low stress group (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stressful events correlated with elevated levels of MDSC
Number of subjects: 16
Study: 19195510

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (TAXUS)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Residual edge plaque burden
Number of subjects: 531
Study: 16987347

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg intravenously
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 15190232

Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SPECT analysis using [123I]‐FP‐CIT
Number of subjects: 36
Study: 10357732

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet (1.7 g phytosterols/d for 30 d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control diet (prepared foods alone)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 32
Study: 8952863

Group type: EXPERIMENTAL
Intervention: Intravenous heparin administration with tissue plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous or intravenous heparin use with streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintaining aPTT in the 55‐70 second range
Number of subjects: 0
Study: 2010166

Group type: EXPERIMENTAL
Intervention: Standardized 355 kcal mixed‐liquid meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study: 6125205

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine 200 mg or 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsule preparations of diazepam
Number of subjects: 0
Study: 30394805

Group type: EXPERIMENTAL
Intervention: Daflon for 1 month
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Daflon for 3 months
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 450
Study: 30489516

Group type: EXPERIMENTAL
Intervention: EB-001
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26599796

Group type: EXPERIMENTAL
Intervention: Saline flush (20 mL normal saline) after rocuronium administration
Number of subjects: 48
Study: 24271264

Group type: EXPERIMENTAL
Intervention: Combined treatment group (CT, n = 61)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard care group (SC, n = 61)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 22388610

Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise (15 min/d, 3 times a week for 8 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 47
Study: 20400266

Group type: EXPERIMENTAL
Intervention: Quebec Back Pain Disability Scale (administered pre-treatment and post-treatment)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Quebec Back Pain Disability Scale score change expressed in percentage
Number of subjects: 212
Study: 18385466

Group type: EXPERIMENTAL
Intervention: Solid food (300 kcal) and water ad libitum
Number of subjects: 16
Study: 15529306

Group type: EXPERIMENTAL
Intervention: Low‐radiation dose spiral computed tomography (LDCT)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 1660
Study: 12457268

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (via ingestion of a mixture of essential amino acids excluding tryptophan)
Number of subjects: 24
Study: 10499652

Group type: EXPERIMENTAL
Intervention: Group A (n = 10): standard heparinization (300 IU/kg) plus two doses of purified antithrombin III (1000 IU each)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group GA (n = 10): 200 IU/kg heparin, continuous infusion of heparin (100 IU/kg/h) and gabexate mesilate (2 mg/kg/h) plus the same dose of antithrombin III as group A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group C, n = 10): standard heparinization (300 IU/kg)
Number of subjects: 30
Study: 7573999

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (50 micrograms.kg‐1.min‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2019163

Group type: EXPERIMENTAL
Intervention: 1 percent phenylephrine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 4 percent lidocaine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 1 percent phenylephrine + 4 percent lidocaine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 5 percent cocaine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 1 percent phenylephrine + Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 5 percent cocaine + Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 2 percent viscous lidocaine (sniffed)
Number of subjects: 107
Study: 6818588

Group type: EXPERIMENTAL
Intervention: 2.0 mg nicotine cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.2 mg nicotine cigarettes
Number of subjects: 0
Study: 31725087

Group type: EXPERIMENTAL
Intervention: Fluoroscopy‐based navigated guidance of lag screw length and position
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 31
Study: 30286625

Group type: EXPERIMENTAL
Intervention: On-Pump Coronary Artery Bypass (ONCAB)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Off-Pump Coronary Artery Bypass (OPCAB)
Number of subjects: 308
Study: 29089063

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™, Elanco) at 20 mg/kg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Afoxolaner (Nexgard®, Merial) at 2.5 mg/kg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lotilaner
Number of subjects: 111
Study: 26981577

Group type: EXPERIMENTAL
Intervention: Oral phage therapy (T4-like coliphages or commercial Russian coliphage product)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral phage therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 120